Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis

Registry ID

EUCTR2012-004019-29

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Novartis Pharma AG

Start date

2013-10-07

Completion date

2014-01-22

Last update

2026-08-16

Conditions

• Relapsing multiple sclerosis

Summary

To evaluate the efficacy of three doses of AIN457 in reducing the number of new Gadolinium-enhancing lesions on MRI compared to placebo

Locations

• , , Italy
• , , Belgium
• , , Sweden
• , , Germany
• , , Czechia
• , , Finland
• , , Spain
• , , Poland

Related clinical trials

• ROAD: Retrospective Analysis of Ocrelizumab Use in Older Adults: A Real-World Data Analysis

View on source registry